Condition: Advanced Solid Tumor · Non Small Cell Lung Cancer · HER2 Mutations · Sponsor: Anbogen Therapeutics, Inc.
A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)
This description comes directly from the study's public registry record.
Anbogen · +886-2-2742-1839 · clinicaltrial@anbogen.com
Always discuss trial participation with your own doctor first.
| Taichung Veterans General Hospital | Taichung, Taiwan | Recruiting |
| National Cheng Kung University Hospital | Tainan, Taiwan | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
| Taipei Medical Univresity Hospital | Taipei, Taiwan | Recruiting |
| Chang Gung Memorial Hospital, Linkou | Taoyuan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05532696